Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Stock Information for Turnstone Biologics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Turnstone Biologics Corp.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.